The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Biogen Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...